

**Boehringer Ingelheim is Pleased to Invite You to Join Our Virtual Symposium**  
Available on demand from 09:00 CET September 14

## Treatment Options for Non-Small Cell Lung Cancer

During this Symposium, a faculty of experts will discuss second-line treatment decisions for non-mutated NSCLC adenocarcinoma, first-line treatment decisions for patients with NSCLC and uncommon EGFR mutations, and emerging strategies for the treatment of NSCLC.

### Welcome and Introduction

**Chair: Tanja Čufer**

*Medical Faculty, University of Ljubljana, Slovenia  
University Clinic Golnik, Slovenia*

### Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma

**Silvia Novello**

*University of Turin, Italy  
San Luigi Gonzaga Hospital, Orbassano, Italy*

### Uncommon EGFR Mutations

**Xiuning Le**

*The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

### The Future of NSCLC

**Melissa Johnson**

*Sarah Cannon Research Institute, Nashville, TN, USA*

### Key Insights and Closing Remarks

**Chair: Tanja Čufer**

*Medical Faculty, University of Ljubljana, Slovenia  
University Clinic Golnik, Slovenia*

**Please join us for a live Q&A event on 22 September 2020 at 17:00-17:30 CET**

